 LONDON and NEW YORK, Dec. 05, 2019 GLOBE NEWSWIRE -- MeiraGTx Holdings plc MGTX, a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinsons disease-focused RD; Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus on MeiraGTxs investigational gene therapy candidate AAV-GAD in development for the treatment of Parkinsons disease. MeiraGTxs president and CEO, Alexandria Forbes, Ph.D., will be joined by additional members of the senior leadership team, in addition to leading clinicians and researchers, to discuss the current Parkinsons disease treatment landscape and results from Phase 1 and Phase 2 clinical trials of AAV-GAD. 